Nucleic acids encoding antibodies to CCR2

US9238691B2 · kind B2 · utility

Assignees

• PFIZER INC. · US
• Amgen Fremont Inc. · US

Inventors

• Ronald P. Gladue · Stonington, US
• Bradley Keller · Chesterfield, US
• Shinji Ogawa · Chesterfield, US
• Arvind Rajpal · San Francisco, US
• Laurie A. Tylaska · Preston, US
• Shelley Sims Belouski · Camarillo, US
• Larry Green · San Francisco, US
• Meina Liang · Danville, US

Key dates

• Filing date: Apr 3, 2014
• Grant date: Jan 19, 2016
• Expiry date: Apr 3, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.